These emerging therapies, especially if combined with repurposed drugs and Pax6-enhancing agents, could significantly improve aniridia management, benefiting the over 7000 patients with congenital aniridia in the EU by offering rapid and accessible treatment options. Here, PAX6 is linked to isolated aniridia.